scholarly journals Antiviral Activity of Total Flavonoid Extracts fromSelaginella moellendorffiiHieron against Coxsackie Virus B3In VitroandIn Vivo

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Dan Yin ◽  
Juan Li ◽  
Xiang Lei ◽  
Yimei Liu ◽  
Zhanqiu Yang ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Inhibitory Concentration ◽  
Colorimetric Assay ◽  
Total Flavonoid ◽  
Coxsackie Virus ◽  
Mtt Colorimetric Assay ◽  
Diphenyl Tetrazolium Bromide ◽  
Selaginella Moellendorffii

The antiviral activity of total flavonoid extracts fromSelaginella moellendorffiiHieron and its main constituents amentoflavone were investigated against coxsackie virus B3 (CVB3). When added during or after viral infection, the extracts and amentoflavone prevented the cytopathic effect (CPE) of CVB3, as demonstrated in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay, with a 50% inhibitory concentration (IC50) from19±1.6to41±1.2 μg/mL and25±1.2to52±0.8 μg/mL, respectively. KM mice were used as animal models to test the extracts' activityin vivo. Oral administration of the total flavonoid extracts at 300 mg/kg/day significantly reduced mean viral titers in the heart and kidneys as well as mortality after infection for 15 days. The experimental results demonstrate thatin vitroandin vivothe model mice infected with CVB3 can be effectively treated by the total flavonoid extracts fromSelaginella moellendorffiiHieron.

scholarly journals Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo

2009 ◽  
Vol 154 (4) ◽  
pp. 601-607 ◽  
Author(s):  
Qiong Zhong ◽  
Zhanqiu Yang ◽  
Yuanyuan Liu ◽  
Haiying Deng ◽  
Hong Xiao ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Coxsackie Virus

In vitro and in vivo antiviral activity of a fluoronucleoside analog, NCC, against Coxsackie virus B3

2021 ◽  
Vol 65 (01) ◽  
pp. 58-67
Author(s):  
Yafeng Wang ◽  
Xiaokai Zhuan ◽  
Youmei Peng ◽  
Qing Li ◽  
Chenzheng Huang ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Coxsackie Virus ◽  
Coxsackie Virus B3

scholarly journals F127/Cisplatin Microemulsions: In Vitro, In Vivo and Computational Studies

2021 ◽  
Vol 11 (7) ◽  
pp. 3006
Author(s):  
Saman Sargazi ◽  
Mohammad Reza Hajinezhad ◽  
Mahmood Barani ◽  
Mahwash Mukhtar ◽  
Abbas Rahdar ◽  
...  
Keyword(s):  
Liver Enzymes ◽  
Colorimetric Assay ◽  
Morphological Changes ◽  
Effective Strategies ◽  
In Vivo Experiments ◽  
Mtt Colorimetric Assay ◽  
Male Wistar Rats

The development of effective strategies for local administration of chemotherapeutic drugs, thus minimizing the adverse side effects to patients, is one of the key challenges in biomedicine and cancer research. This work reports the formulation and characterization of PluronicF127 microemulsions to enhance the bioavailability of Cisplatin (Cis). The size of Cis microemulsion was about 12.0 nm, as assessed by dynamic light scattering analysis. In vitro cytotoxic activity of free Cis and F127/Cis microemulsions were studied on malignant (C152 and MCF7) and normal (HUVEC) cells via tetrazolium (MTT) colorimetric assay. Cell morphology was also monitored. In vitro assessments revealed thatF127/Cis microemulsions induced cytotoxicity/morphological changes to a lesser extent than free Cis. Regarding in vivo experiments, F127/Cis microemulsions were injected intraperitoneally at 7 and 14 mg/kg doses into adult male Wistar rats to assess histologic and biochemical changes. In this case, the bulk Cis group caused severe histopathological changes and significant increases in serum liver enzymes and serum kidney function markers. The group treated with the 14 mg/kg dose of F127/Cis microemulsions also showed severe fatty changes and significant increases in serum liver enzymes, blood urea nitrogen, and creatinine levels. The group treated with the low dose of nano-Cis showed a significant increase in serum liver enzymes levels accompanied by mild fatty changes of the liver. Theoretical surveys were performed to get an understanding of the interplay between F127 and Cis. Results reveal that hydrogen bonding (HB) interactions with F127have an influence on the molecular properties of Cis and may playa role in the lower toxicity of F127/Cis in comparison to free Cis.

Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo

2021 ◽  
pp. 174204
Author(s):  
Yiming Cao ◽  
En Lei ◽  
Lei Li ◽  
Jin Ren ◽  
Xiaoyang He ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Enterovirus A71

scholarly journals Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model

2021 ◽  
Vol 14 (4) ◽  
pp. 294
Author(s):  
Eric G. Romanowski ◽  
Islam T. M. Hussein ◽  
Steven C. Cardinale ◽  
Michelle M. Butler ◽  
Lucas R. Morin ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Topical Treatment ◽  
Antiviral Agent ◽  
Human Adenovirus ◽  
Treatment Groups ◽  
Ocular Infections ◽  
The Mean ◽  
Eye Infection

Presently, there is no FDA- or EMA-approved antiviral for the treatment of human adenovirus (HAdV) ocular infections. This study determined the antiviral activity of filociclovir (FCV) against ocular HAdV isolates in vitro and in the Ad5/NZW rabbit ocular model. The 50% effective concentrations (EC50) of FCV and cidofovir (CDV) were determined for several ocular HAdV types using standard plaque reduction assays. Rabbits were topically inoculated in both eyes with HAdV5. On day 1, the rabbits were divided into four topical treatment groups: (1) 0.5% FCV 4x/day × 10 d; (2) 0.1% FCV 4x/day × 10 d; (3) 0.5% CDV 2x/day × 7 d; (4) vehicle 4x/day × 10 d. Eyes were cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14. The resulting viral eye titers were determined using standard plaque assays. The mean in vitro EC50 for FCV against tested HAdV types ranged from 0.50 to 4.68 µM, whereas those treated with CDV ranged from 0.49 to 30.3 µM. In vivo, compared to vehicle, 0.5% FCV, 0.1% FCV, and 0.5% CDV produced lower eye titers, fewer numbers of positive eye cultures, and shorter durations of eye infection. FCV demonstrated anti-adenovirus activity in vitro and in vivo.

scholarly journals Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

2013 ◽  
Vol 2013 ◽  
pp. 1-21 ◽  
Author(s):  
Giuseppe Sautto ◽  
Nicasio Mancini ◽  
Giacomo Gorini ◽  
Massimo Clementi ◽  
Roberto Burioni
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Side Effects ◽  
Antiviral Activity ◽  
The Other ◽  
Viral Escape ◽  
Passive Immunotherapy ◽  
Medical Need

More than 150 arboviruses belonging to different families are known to infect humans, causing endemic infections as well as epidemic outbreaks. Effective vaccines to limit the occurrence of some of these infections have been licensed, while for the others several new immunogens are under development mostly for their improvements concerning safety and effectiveness profiles. On the other hand, specific and effective antiviral drugs are not yet available, posing an urgent medical need in particular for emergency cases. Neutralizing monoclonal antibodies (mAbs) have been demonstrated to be effective in the treatment of several infectious diseases as well as in preliminaryin vitroandin vivomodels of arbovirus-related infections. Given their specific antiviral activity as well-tolerated molecules with limited side effects, mAbs could represent a new therapeutic approach for the development of an effective treatment, as well as useful tools in the study of the host-virus interplay and in the development of more effective immunogens. However, before their use as candidate therapeutics, possible hurdles (e.g., Ab-dependent enhancement of infection, occurrence of viral escape variants) must be carefully evaluated. In this review are described the main arboviruses infecting humans and candidate mAbs to be possibly used in a future passive immunotherapy.

Template-dependent biosynthesis of poly(G)·poly(C) and its antiviral activity in vitro and in vivo

1998 ◽  
Vol 38 (2) ◽  
pp. 131-140 ◽  
Author(s):  
M.A Surzhik ◽  
L.M Vilner ◽  
A.L Katchurin ◽  
A.L Timkovskii
Keyword(s):  
Antiviral Activity

Exploration of the in vitro cytotoxic and antiviral activities of different medicinal plants against infectious bursal disease (IBD) virus

2014 ◽  
Vol 9 (5) ◽  
pp. 531-542 ◽  
Author(s):  
Waqas Ahmad ◽  
Sohail Ejaz ◽  
Khaleeq Anwar ◽  
Muhammad Ashraf
Keyword(s):  
Medicinal Plants ◽  
Colorimetric Assay ◽  
Rna Virus ◽  
Infectious Bursal Disease ◽  
Dna Viruses ◽  
Mtt Colorimetric Assay ◽  
Bursal Disease ◽  
Dried Fruit ◽  
Antiviral Activities

AbstractInfectious bursal disease (IBD) caused by non-enveloped double stranded RNA virus is an acute and contagious poultry disease. Outbreak of IBD could result in 10–75% mortality of the birds; hence it has gained socio-economic importance worldwide. Medicinal plants have shown broad spectrum anti-viral activities against RNA and DNA viruses. Moringa oleifera Lam (MOL), Phyllanthus emblicus Linn (PEL), Glycyrrhiza glabra Linn (GGL), and Eugenia jambolana Lam (EJL) are commonly available medicinal plants of the sub-continent and exhibited anti-viral potential against different viruses. Ethanolic extracts of the leaves of MOL and EJL, roots of GGL and dried fruit of PEL were investigated for their cytotoxic and anti-viral potential against IBD virus using MTT colorimetric assay and anti-viral assay. Significant anti-viral potential (P<0.001) was demonstrated at concentrations 12.5, 25, 50 and 100 µg ml−1 of GGL, PEL, MOL and EJL, respectively, with no cytotoxicity. Data also spotlighted that all tested plant extracts possess significant anti-viral potential and this trend was higher in GGL followed by PEL, MOL, and EJL. The data undoubtedly conclude that these medicinal plants contain several health beneficial phyto-chemicals which got significant anti-viral potential and effectively be utilized against IBD virus. Moreover, the outcomes of this study provide a platform on the way to discover novel anti-viral agents against IBD virus and other viruses from plant origin.

Sign in / Sign up

Export Citation Format

Share Document